BIONXT SOLUTIONS INC (BNXTF)
BNXTF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How BNXTF actually reacts to news — the realized, point-in-time move the market made, measured across 99 labeled events over the last three years with zero look-ahead.
BNXTF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 5% | 67 |
| 30-min | 0.00% | 9% | 67 |
| 60-min | 0.00% | 12% | 67 |
| to close | 0.00% | 31% | 67 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BNXTF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BNXTF's baseline. Nothing else.
Recent BNXTF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies | Press release | ACCESS Newswire | — | — | |
| BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies | Press release | ACCESS Newswire | — | — | |
| BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline | Press release | ACCESS Newswire | — | — | |
| BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline | Press release | ACCESS Newswire | — | — | |
| BioNxt Solutions Announces Option Grants | Press release | ACCESS Newswire | — | — | |
| BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption | Press release | ACCESS Newswire | — | — | |
| BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants | Press release | ACCESS Newswire | +0.00% | +3.18% | |
| BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum | Press release | ACCESS Newswire | — | — | |
| BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) | Press release | ACCESS Newswire | +0.00% | +19.59% | |
| BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries | Press release | ACCESS Newswire | — | +0.00% | |
| BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy | Press release | ACCESS Newswire | — | — | |
| BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform | Press release | ACCESS Newswire | +0.00% | -3.34% | |
| BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Announces Closing of Shares for Debt Settlement | Press release | ACCESS Newswire | — | — | |
| BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion | Press release | ACCESS Newswire | — | — | |
| BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) | Press release | ACCESS Newswire | +0.00% | +4.12% | |
| BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF | Press release | ACCESS Newswire | — | — | |
| Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies | Press release | ACCESS Newswire | +0.00% | +6.08% | |
| BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments | Press release | ACCESS Newswire | +0.00% | +1.27% | |
| BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform | Press release | ACCESS Newswire | +0.00% | -0.42% | |
| BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies | Press release | ACCESS Newswire | -0.40% | +1.07% | |
| BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization | Press release | ACCESS Newswire | +2.53% | +2.93% | |
| BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug | Press release | PR Newswire | +0.00% | +0.11% | |
| BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study | Press release | ACCESS Newswire | -7.97% | -6.77% | |
| BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis | Press release | ACCESS Newswire | +0.00% | -0.92% | |
| BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities | Press release | ACCESS Newswire | +0.00% | +2.68% | |
| BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform | Press release | ACCESS Newswire | — | — | |
| BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization | Press release | ACCESS Newswire | +0.00% | -1.56% | |
| BioNxt Solutions Announces Closing of Shares for Debt Settlement | Press release | ACCESS Newswire | +0.00% | -0.58% | |
| Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals | Press release | ACCESS Newswire | +0.00% | -0.58% | |
| BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development | Press release | ACCESS Newswire | +0.00% | +1.89% | |
| BioNxt Announces Shares for Debt Settlement | Press release | ACCESS Newswire | +0.00% | +1.89% | |
| BioNxt Solutions Completes Up-Listing to The OTCQB Market | Press release | ACCESS Newswire | +0.00% | +0.99% | |
| Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt | Press release | ACCESS Newswire | — | — | |
| Promotional Activity Engagements | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline | Press release | ACCESS Newswire | -6.75% | — | |
| BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement | Press release | ACCESS Newswire | +0.00% | -5.06% | |
| BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment | Press release | ACCESS Newswire | +0.00% | -0.27% | |
| BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| BioNxt Solutions Announces Convertible Debenture Unit Private Placement | Press release | ACCESS Newswire | +0.00% | +28.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BNXTF section they belong to.
Where else BNXTF is measured.
BNXTF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BIONXT SOLUTIONS INC's median reaction calculated?
Every labeled BNXTF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 99 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 9% of BNXTF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BNXTF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.